Selected research
Industry Research
Sunitinib Generics Industry Research Report 2026
Market perspective
The global Sunitinib Generics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Sunitinib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Sunitinib Generics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Sunitinib Generics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Sunitinib Generics include Aprazer Healthcare, Taj Pharma, Teva, Zydus, Hansoh Pharma, Hunan Kelun Pharmaceutical, Qilu Pharmaceutical, CSPC Pharmaceutical and Chia Tai Tianqing, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Sunitinib Generics market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sunitinib Generics Market by Company
Aprazer Healthcare
Taj Pharma
Teva
Zydus
Hansoh Pharma
Hunan Kelun Pharmaceutical
Qilu Pharmaceutical
CSPC Pharmaceutical
Chia Tai Tianqing
Sunitinib Generics Segment by Type
50mg per Unit
37.5mg per Unit
20mg per Unit
12.5mg per Unit
Sunitinib Generics Segment by Application
Pancreatic Neuroendocrine Tumors
Gastrointestinal Stromal Tumors
Renal cell Carcinoma
Other
Sunitinib Generics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sunitinib Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sunitinib Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sunitinib Generics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Sunitinib Generics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Sunitinib Generics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Sunitinib Generics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50mg per Unit
- 37.5mg per Unit
- 20mg per Unit
- 12.5mg per Unit
Applications
- Pancreatic Neuroendocrine Tumors
- Gastrointestinal Stromal Tumors
- Renal cell Carcinoma
- Other
Companies covered
- Aprazer Healthcare
- Taj Pharma
- Teva
- Zydus
- Hansoh Pharma
- Hunan Kelun Pharmaceutical
- Qilu Pharmaceutical
- CSPC Pharmaceutical
- Chia Tai Tianqing
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Sunitinib Generics Market Size (2021-2032)
- 2.2.2 Global Sunitinib Generics Sales (2021-2032)
- 2.2.3 Global Sunitinib Generics Market Average Price (2021-2032)
- 2.3 Sunitinib Generics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 50mg per Unit
- 2.3.3 37.5mg per Unit
- 2.3.4 20mg per Unit
- 2.3.5 12.5mg per Unit
- 2.4 Sunitinib Generics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pancreatic Neuroendocrine Tumors
- 2.4.3 Gastrointestinal Stromal Tumors
- 2.4.4 Renal cell Carcinoma
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Sunitinib Generics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sunitinib Generics Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Sunitinib Generics Revenue of Manufacturers (2021-2026)
- 3.4 Global Sunitinib Generics Average Price by Manufacturers (2021-2026)
- 3.5 Global Sunitinib Generics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sunitinib Generics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sunitinib Generics, Product Type & Application
- 3.8 Global Manufacturers of Sunitinib Generics, Established Date
- 3.9 Global Sunitinib Generics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aprazer Healthcare
- 4.1.1 Aprazer Healthcare Company Information
- 4.1.2 Aprazer Healthcare Business Overview
- 4.1.3 Aprazer Healthcare Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Aprazer Healthcare Sunitinib Generics Product Portfolio
- 4.1.5 Aprazer Healthcare Recent Developments
- 4.2 Taj Pharma
- 4.2.1 Taj Pharma Company Information
- 4.2.2 Taj Pharma Business Overview
- 4.2.3 Taj Pharma Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Taj Pharma Sunitinib Generics Product Portfolio
- 4.2.5 Taj Pharma Recent Developments
- 4.3 Teva
- 4.3.1 Teva Company Information
- 4.3.2 Teva Business Overview
- 4.3.3 Teva Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Sunitinib Generics Product Portfolio
- 4.3.5 Teva Recent Developments
- 4.4 Zydus
- 4.4.1 Zydus Company Information
- 4.4.2 Zydus Business Overview
- 4.4.3 Zydus Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Zydus Sunitinib Generics Product Portfolio
- 4.4.5 Zydus Recent Developments
- 4.5 Hansoh Pharma
- 4.5.1 Hansoh Pharma Company Information
- 4.5.2 Hansoh Pharma Business Overview
- 4.5.3 Hansoh Pharma Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hansoh Pharma Sunitinib Generics Product Portfolio
- 4.5.5 Hansoh Pharma Recent Developments
- 4.6 Hunan Kelun Pharmaceutical
- 4.6.1 Hunan Kelun Pharmaceutical Company Information
- 4.6.2 Hunan Kelun Pharmaceutical Business Overview
- 4.6.3 Hunan Kelun Pharmaceutical Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hunan Kelun Pharmaceutical Sunitinib Generics Product Portfolio
- 4.6.5 Hunan Kelun Pharmaceutical Recent Developments
- 4.7 Qilu Pharmaceutical
- 4.7.1 Qilu Pharmaceutical Company Information
- 4.7.2 Qilu Pharmaceutical Business Overview
- 4.7.3 Qilu Pharmaceutical Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Qilu Pharmaceutical Sunitinib Generics Product Portfolio
- 4.7.5 Qilu Pharmaceutical Recent Developments
- 4.8 CSPC Pharmaceutical
- 4.8.1 CSPC Pharmaceutical Company Information
- 4.8.2 CSPC Pharmaceutical Business Overview
- 4.8.3 CSPC Pharmaceutical Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CSPC Pharmaceutical Sunitinib Generics Product Portfolio
- 4.8.5 CSPC Pharmaceutical Recent Developments
- 4.9 Chia Tai Tianqing
- 4.9.1 Chia Tai Tianqing Company Information
- 4.9.2 Chia Tai Tianqing Business Overview
- 4.9.3 Chia Tai Tianqing Sunitinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Chia Tai Tianqing Sunitinib Generics Product Portfolio
- 4.9.5 Chia Tai Tianqing Recent Developments
5 Global Sunitinib Generics Market Scenario by Region
- 5.1 Global Sunitinib Generics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sunitinib Generics Sales by Region: 2021-2032
- 5.2.1 Global Sunitinib Generics Sales by Region: 2021-2026
- 5.2.2 Global Sunitinib Generics Sales by Region: 2027-2032
- 5.3 Global Sunitinib Generics Revenue by Region: 2021-2032
- 5.3.1 Global Sunitinib Generics Revenue by Region: 2021-2026
- 5.3.2 Global Sunitinib Generics Revenue by Region: 2027-2032
- 5.4 North America Sunitinib Generics Market Facts & Figures by Country
- 5.4.1 North America Sunitinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Sunitinib Generics Sales by Country (2021-2032)
- 5.4.3 North America Sunitinib Generics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Sunitinib Generics Market Facts & Figures by Country
- 5.5.1 Europe Sunitinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Sunitinib Generics Sales by Country (2021-2032)
- 5.5.3 Europe Sunitinib Generics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Sunitinib Generics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Sunitinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Sunitinib Generics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Sunitinib Generics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Sunitinib Generics Market Facts & Figures by Country
- 5.7.1 South America Sunitinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Sunitinib Generics Sales by Country (2021-2032)
- 5.7.3 South America Sunitinib Generics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Sunitinib Generics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Sunitinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Sunitinib Generics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Sunitinib Generics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Sunitinib Generics Sales by Type (2021-2032)
- 6.1.1 Global Sunitinib Generics Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Sunitinib Generics Sales Market Share by Type (2021-2032)
- 6.2 Global Sunitinib Generics Revenue by Type (2021-2032)
- 6.2.1 Global Sunitinib Generics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Sunitinib Generics Revenue Market Share by Type (2021-2032)
- 6.3 Global Sunitinib Generics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Sunitinib Generics Sales by Application (2021-2032)
- 7.1.1 Global Sunitinib Generics Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Sunitinib Generics Sales Market Share by Application (2021-2032)
- 7.2 Global Sunitinib Generics Revenue by Application (2021-2032)
- 7.2.1 Global Sunitinib Generics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Sunitinib Generics Revenue Market Share by Application (2021-2032)
- 7.3 Global Sunitinib Generics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Sunitinib Generics Value Chain Analysis
- 8.1.1 Sunitinib Generics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Sunitinib Generics Production Mode & Process
- 8.2 Sunitinib Generics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Sunitinib Generics Distributors
- 8.2.3 Sunitinib Generics Customers
9 Global Sunitinib Generics Analyzing Market Dynamics
- 9.1 Sunitinib Generics Industry Trends
- 9.2 Sunitinib Generics Industry Drivers
- 9.3 Sunitinib Generics Industry Opportunities and Challenges
- 9.4 Sunitinib Generics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst